NO312812B1 - Anvendelse av preventivt eller terapeutisk medikament for sykdommen Alzheimer eller senildemens - Google Patents

Anvendelse av preventivt eller terapeutisk medikament for sykdommen Alzheimer eller senildemens Download PDF

Info

Publication number: NO312812B1
Authority: NO; Norway
Prior art keywords: compound; cells; alzheimer; preventive; therapeutic drug
Prior art date: 1996-08-27

Application number

NO19973912A

Other languages

English (en)

Norwegian (no)

Other versions

NO973912D0 (no

NO973912L (no

Inventor

Ikuro Maruyama

Kazuhiro Abeyama

Hiroyuki Masayasu

Original Assignee

Nattermann A & Cie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1997-08-26

Publication date

2002-07-08

1997-08-26 Application filed by Nattermann A & Cie filed Critical Nattermann A & Cie

1997-08-26 Publication of NO973912D0 publication Critical patent/NO973912D0/no

1998-03-02 Publication of NO973912L publication Critical patent/NO973912L/no

2002-07-08 Publication of NO312812B1 publication Critical patent/NO312812B1/no

Links

208000024827 Alzheimer disease Diseases 0.000 title claims description 14
206010039966 Senile dementia Diseases 0.000 title claims description 4
230000003449 preventive effect Effects 0.000 title description 7
229940126585 therapeutic drug Drugs 0.000 title description 6
239000003814 drug Substances 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 4
238000011282 treatment Methods 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 24
229940126062 Compound A Drugs 0.000 description 23
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 23
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
230000016273 neuron death Effects 0.000 description 8
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 7
108010039918 Polylysine Proteins 0.000 description 7
239000002609 medium Substances 0.000 description 7
229920000656 polylysine Polymers 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000006285 cell suspension Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000000034 method Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 4
XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 3
208000037259 Amyloid Plaque Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000030833 cell death Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000012190 sympathetic paraganglioma Diseases 0.000 description 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
229960001685 tacrine Drugs 0.000 description 2
CLKJBNAGQKQOAV-UHFFFAOYSA-N 2-hydroxy-1,2-benzoselenazol-3-one Chemical compound C1=CC=CC2=C1[se]N(O)C2=O CLKJBNAGQKQOAV-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000008344 brain blood flow Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229950010033 ebselen Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000000243 solution Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO19973912A 1996-08-27 1997-08-26 Anvendelse av preventivt eller terapeutisk medikament for sykdommen Alzheimer eller senildemens NO312812B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP22551296		1996-08-27

Publications (3)

Publication Number	Publication Date
NO973912D0 NO973912D0 (no)	1997-08-26
NO973912L NO973912L (no)	1998-03-02
NO312812B1 true NO312812B1 (no)	2002-07-08

Family

ID=16830487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19973912A NO312812B1 (no)	1996-08-27	1997-08-26	Anvendelse av preventivt eller terapeutisk medikament for sykdommen Alzheimer eller senildemens

Country Status (28)

Country	Link
US (1)	US5948800A (cs)
EP (1)	EP0826370B1 (cs)
KR (1)	KR20000035859A (cs)
CN (1)	CN1112922C (cs)
AT (1)	ATE219361T1 (cs)
AU (2)	AU3866997A (cs)
BR (1)	BR9711259A (cs)
CA (1)	CA2213794C (cs)
CZ (1)	CZ295364B6 (cs)
DE (2)	DE59707550D1 (cs)
DK (1)	DK0826370T3 (cs)
EE (1)	EE03953B1 (cs)
ES (1)	ES2177849T3 (cs)
FI (1)	FI119622B (cs)
HU (1)	HU225264B1 (cs)
IL (1)	IL127113A (cs)
LT (1)	LT4602B (cs)
LV (1)	LV12251B (cs)
NO (1)	NO312812B1 (cs)
NZ (1)	NZ332292A (cs)
PL (1)	PL188481B1 (cs)
PT (1)	PT826370E (cs)
SI (1)	SI9720060B (cs)
TR (1)	TR199700858A2 (cs)
TW (1)	TW501925B (cs)
UA (1)	UA59367C2 (cs)
WO (2)	WO1998008511A1 (cs)
ZA (1)	ZA977644B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2145065T3 (es) *	1993-10-27	2000-07-01	Daiichi Seiyaku Co	Preparacion granular.
JP2000016935A (ja) *	1998-07-01	2000-01-18	Dai Ichi Seiyaku Co Ltd	シクロオキシゲナーゼ阻害剤
AU3457300A (en)	1999-03-31	2000-10-16	Daiichi Pharmaceutical Co., Ltd.	Substrates for thioredoxin reductase
WO2003010143A1 (en)	2001-07-26	2003-02-06	Samsung Electronics Co., Ltd.	Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
WO2003010154A1 (en) *	2001-07-26	2003-02-06	Samsung Electronics Co. Ltd.	Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
WO2003010153A1 (en)	2001-07-26	2003-02-06	Samsung Electronics Co. Ltd.	N-alkyl-n-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses
GB201102248D0 (en)	2011-02-09	2011-03-23	Isis Innovation	Treatment of bipolar disorder
CN103965188A (zh) *	2013-01-29	2014-08-06	中山大学	含硒多奈哌齐类似物
EP2950102A1 (en)	2014-05-30	2015-12-02	Biocross, S.L.	Method for the diagnosis of alzheimer s disease and mild cognitive impairment
US10058542B1 (en)	2014-09-12	2018-08-28	Thioredoxin Systems Ab	Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3067699A1 (en)	2015-03-11	2016-09-14	Neuron Bio, S.A.	Method for diagnosing alzheimer's disease
PL237739B1 (pl)	2018-06-06	2021-05-17	Univ Gdanski	Genisteina do zastosowania do leczenia choroby Alzheimera
CN113116888B (zh) *	2021-04-19	2022-08-26	上海兴糖生物技术有限公司	依布硒啉的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3616923A1 (de) *	1986-05-20	1987-11-26	Nattermann A & Cie	Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
DE3638124C2 (de) *	1986-11-08	1996-09-05	Nattermann A & Cie	Neue pharmazeutische Verwendung von Ebselen
JPH01131113A (ja) *	1987-08-27	1989-05-24	Dai Ichi Seiyaku Co Ltd	脳障害治療剤
JPH0238591A (ja)	1988-07-27	1990-02-07	Fujikura Ltd	高純度銅の製造方法
DE4024885C2 (de) *	1990-08-06	2002-07-18	Nattermann A & Cie	Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5385726A (en) *	1990-08-06	1995-01-31	Rhone-Poulenc Rorer Gmbh	Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
FR2669633B1 (fr) *	1990-11-23	1993-01-22	Adir	Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH07233056A (ja) *	1993-09-03	1995-09-05	Dai Ichi Seiyaku Co Ltd	リポキシゲナーゼ阻害剤

1997
- 1997-03-17 ES ES97104503T patent/ES2177849T3/es not_active Expired - Lifetime
- 1997-03-17 DE DE59707550T patent/DE59707550D1/de not_active Expired - Fee Related
- 1997-03-17 PT PT97104503T patent/PT826370E/pt unknown
- 1997-03-17 DK DK97104503T patent/DK0826370T3/da active
- 1997-03-17 AT AT97104503T patent/ATE219361T1/de not_active IP Right Cessation
- 1997-03-17 EP EP97104503A patent/EP0826370B1/de not_active Expired - Lifetime
- 1997-04-07 SI SI9720060A patent/SI9720060B/sl not_active IP Right Cessation
- 1997-04-07 BR BR9711259A patent/BR9711259A/pt not_active Application Discontinuation
- 1997-04-07 IL IL12711397A patent/IL127113A/xx not_active IP Right Cessation
- 1997-04-07 WO PCT/DE1997/000701 patent/WO1998008511A1/de not_active Ceased
- 1997-04-07 EE EEP199900007A patent/EE03953B1/xx not_active IP Right Cessation
- 1997-04-07 HU HU9903213A patent/HU225264B1/hu not_active IP Right Cessation
- 1997-04-07 CZ CZ1999317A patent/CZ295364B6/cs not_active IP Right Cessation
- 1997-04-07 NZ NZ332292A patent/NZ332292A/en unknown
- 1997-04-07 CN CN97195890A patent/CN1112922C/zh not_active Expired - Fee Related
- 1997-07-04 UA UA99010526A patent/UA59367C2/uk unknown
- 1997-08-04 US US08/905,530 patent/US5948800A/en not_active Expired - Lifetime
- 1997-08-04 DE DE19733690A patent/DE19733690A1/de not_active Withdrawn
- 1997-08-20 WO PCT/JP1997/002883 patent/WO1998008831A1/ja not_active Ceased
- 1997-08-20 AU AU38669/97A patent/AU3866997A/en not_active Abandoned
- 1997-08-20 KR KR1019997001554A patent/KR20000035859A/ko not_active Ceased
- 1997-08-21 TW TW086112018A patent/TW501925B/zh not_active IP Right Cessation
- 1997-08-25 CA CA002213794A patent/CA2213794C/en not_active Expired - Fee Related
- 1997-08-26 PL PL97321796A patent/PL188481B1/pl not_active IP Right Cessation
- 1997-08-26 AU AU35298/97A patent/AU725534B2/en not_active Ceased
- 1997-08-26 ZA ZA977644A patent/ZA977644B/xx unknown
- 1997-08-26 NO NO19973912A patent/NO312812B1/no not_active IP Right Cessation
- 1997-08-27 TR TR97/00858A patent/TR199700858A2/xx unknown
1998
- 1998-10-22 LV LVP-98-231A patent/LV12251B/lv unknown
- 1998-12-11 FI FI982689A patent/FI119622B/fi not_active IP Right Cessation
1999
- 1999-02-23 LT LT99-016A patent/LT4602B/lt not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU225264B1 (en)	2006-08-28
UA59367C2 (uk)	2003-09-15
NO973912D0 (no)	1997-08-26
AU3866997A (en)	1998-03-19
IL127113A (en)	2003-07-06
CN1223580A (zh)	1999-07-21
WO1998008511A1 (de)	1998-03-05
TR199700858A2 (xx)	1998-03-21
PL188481B1 (pl)	2005-02-28
NO973912L (no)	1998-03-02
CA2213794C (en)	2006-10-03
LV12251B (lv)	1999-08-20
PL321796A1 (en)	1998-03-02
SI9720060B (en)	2001-12-31
BR9711259A (pt)	1999-08-17
FI119622B (fi)	2009-01-30
EE9900007A (et)	1999-06-15
NZ332292A (en)	2001-07-27
EE03953B1 (et)	2003-02-17
DE19733690A1 (de)	1998-03-26
DK0826370T3 (da)	2002-10-07
CA2213794A1 (en)	1998-02-27
CZ295364B6 (cs)	2005-07-13
FI982689L (fi)	1998-12-11
LV12251A (lv)	1999-04-20
ATE219361T1 (de)	2002-07-15
US5948800A (en)	1999-09-07
EP0826370B1 (de)	2002-06-19
KR20000035859A (ko)	2000-06-26
DE59707550D1 (de)	2002-07-25
FI982689A0 (fi)	1998-12-11
ZA977644B (en)	1999-02-26
HK1020317A1 (en)	2000-04-14
LT4602B (lt)	2000-01-25
TW501925B (en)	2002-09-11
HUP9903213A1 (en)	2000-07-28
CZ31799A3 (cs)	1999-11-17
HUP9903213A3 (en)	2000-12-28
SI9720060A (sl)	1999-06-30
AU725534B2 (en)	2000-10-12
AU3529897A (en)	1998-03-05
CN1112922C (zh)	2003-07-02
LT99016A (en)	1999-10-25
ES2177849T3 (es)	2002-12-16
EP0826370A1 (de)	1998-03-04
IL127113A0 (en)	1999-09-22
WO1998008831A1 (en)	1998-03-05
PT826370E (pt)	2002-10-31

Legal Events

Date	Code	Title	Description
2005-05-02	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
Yalin et al.	2012	Strontium ranelate treatment improves oxidative damage in osteoporotic rat model
JP7637050B2 (ja)	2025-02-27	少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ－アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
NO312812B1 (no)	2002-07-08	Anvendelse av preventivt eller terapeutisk medikament for sykdommen Alzheimer eller senildemens
Tain et al.	2010	Melatonin blocks oxidative stress-induced increased asymmetric dimethylarginine
NO315687B1 (no)	2003-10-13	Anvendelse av nebivolol for fremstilling av et anti-aterogent middel
Bi et al.	2022	γ-Glutamylcysteine attenuates amyloid-β oligomers-induced neuroinflammation in microglia via blocking NF-κB signaling pathway
EP2455079B1 (en)	2015-03-18	Composition for the prevention or treatment of bone diseases comprising colforsin daropate
KR100265385B1 (ko)	2000-11-01	순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
Maher et al.	1997	Manipulation of glutathione stores in rat hepatic stellate cells does not alter collagen synthesis
US5962480A (en)	1999-10-05	Drug for ameliorating brain diseases
KR101074030B1 (ko)	2011-10-17	이데솔리드의 신규 용도
US5401725A (en)	1995-03-28	Neovascularization inhibition by adenosine-5'-phosphosulfates
KR100951185B1 (ko)	2010-04-06	상황버섯으로부터 추출한 신경세포 보호용 화합물, 그제조방법 및 상기 화합물을 유효성분으로 함유하는신경세포 보호용 조성물
KR100467471B1 (ko)	2005-01-24	신경세포 보호활성을 갖는 상황버섯 균사체 추출물 및이를 함유하는 퇴행성 뇌신경계 질환의 예방 및 치료제
JPH11501011A (ja)	1999-01-26	神経保護薬としての縮合ベンゾチアゾール類の利用
RU2820163C2 (ru)	2024-05-30	Композиции и способы с использованием по меньшей мере одного глицина или его производного, по меньшей мере одного n-ацетилцистеина или его производного и по меньшей мере одного никотинамидрибозида или предшественника nad+
EP4327811A1 (en)	2024-02-28	Anticancer composition inducing cell senescence and cell death
WO2009028839A1 (en)	2009-03-05	Pharmaceutical composition for preventing or treating bone diseases comprising licochalcone a
EP0005333A1 (en)	1979-11-14	A pharmaceutical composition comprising an amino acid for reducing blood serum prolactin levels
JP2020520904A (ja)	2020-07-16	薬剤、組成物、及びそれに関連する方法
Dalimova et al.	2020	Study of the effects of various polyphenols on proliferative processes and the functional state of liver mitochondria of experimental toxic hepatitis
JP4631069B2 (ja)	2011-02-16	β−アミロイド毒性緩和剤。
Messeha et al.	2023	Flavonoids Activation of Nrf2 and Osteoporosis
KR101430293B1 (ko)	2014-08-18	백금 나노입자를 포함하는 골다공증 치료 또는 예방용 조성물
CN117157074A (zh)	2023-12-01	诱导细胞衰老及细胞死亡的抗癌组合物